Downstream signaling pathways, including the PI3K-Akt-mTOR pathway, the Ras-Raf-MEK-ERK pathway, and the IGF-IR pathway, can become abnormally and persistently activated, enabling tumor cells to evade trastuzumab's effects and develop drug resistance100,101. The gene discussed is AKT1; the disease is neoplasm.